Company:  DENALI THERAPEUTICS INC. (DNLI)
Form Type:  10-Q
Filing Date:  8/6/2019 
CIK:  0001714899 
Address:  161 OYSTER POINT BLVD. 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650) 866-8548 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$30.15  
Change: 
0.305 (1.02%)  
Trade Time: 
09:58 AM EST  
Market Cap: 
$3.19B
Trade DNLI now with 

© 2020  
Description of Business
Neurodegeneration represents one of the most significant unmet medical needs of our time, with few effective therapeutic options available for patients with neurodegenerative diseases. Recent genetic insights are revealing the underlying biology of neurodegeneration and potential drug targets while enabling better patient selection, similar to how genetic insights have transformed the field of oncology. Our scientific strategy is guided by three overarching principles that we believe will significantly increase the probability of success and accelerate the timing to bring effective therapeutics to patients with neurodegenerative diseases: Genetic Pathway Potential - We select our therapeutic targets and disease pathways based on studies that link human genetic variation to the risk of developing a neurodegenerative disease.
Register and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      ITEM 1. FINANCIAL STATEMENTS
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Condensed Consolidated Financial Statements
      ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES
    PART II. OTHER INFORMATION
      ITEM 1. LEGAL PROCEEDINGS
      ITEM 1A. RISK FACTORS
      ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF ...
      ITEM 3. DEFAULTS UPON SENIOR SECURITIES
      ITEM 4. MINE SAFETY DISCLOSURES
      ITEM 5. OTHER INFORMATION
      ITEM 6. EXHIBITS
    EXHIBIT INDEX
    SIGNATURES
  EXHIBIT 31.1
    CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF
  EXHIBIT 31.2
    CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF
  EXHIBIT 32.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
  EXHIBIT 32.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER